ATE427948T1 - Folat-mimetika und deren folatrezeptorbindende konjugate - Google Patents

Folat-mimetika und deren folatrezeptorbindende konjugate

Info

Publication number
ATE427948T1
ATE427948T1 AT02731495T AT02731495T ATE427948T1 AT E427948 T1 ATE427948 T1 AT E427948T1 AT 02731495 T AT02731495 T AT 02731495T AT 02731495 T AT02731495 T AT 02731495T AT E427948 T1 ATE427948 T1 AT E427948T1
Authority
AT
Austria
Prior art keywords
folate
mimetics
receptor
binding conjugates
disclosure relates
Prior art date
Application number
AT02731495T
Other languages
English (en)
Inventor
Mark Green
Christopher Leamon
Chun-Yen Ke
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE427948T1 publication Critical patent/ATE427948T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02731495T 2001-04-24 2002-04-24 Folat-mimetika und deren folatrezeptorbindende konjugate ATE427948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28608201P 2001-04-24 2001-04-24

Publications (1)

Publication Number Publication Date
ATE427948T1 true ATE427948T1 (de) 2009-04-15

Family

ID=23096986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731495T ATE427948T1 (de) 2001-04-24 2002-04-24 Folat-mimetika und deren folatrezeptorbindende konjugate

Country Status (5)

Country Link
US (2) US7875612B2 (de)
EP (1) EP1389209B1 (de)
AT (1) ATE427948T1 (de)
DE (1) DE60231868D1 (de)
WO (1) WO2002085908A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
EP1558585B1 (de) * 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologisch aktive verbindungen
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
EP1620105B1 (de) 2003-04-16 2007-01-10 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido¬3,4-d|pyrimidin-2-yl)-amin derivate als p38 kinase inhibitoren zur behandlung von entzündlichen erkrankungen wie rheumatoider arthritis
EP1629281B1 (de) 2003-05-30 2008-10-29 Purdue Research Foundation Diagnoseverfahren für atherosklerose
JP4590198B2 (ja) * 2004-03-26 2010-12-01 独立行政法人科学技術振興機構 葉酸誘導体の製造方法
US20060135455A1 (en) 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5149620B2 (ja) * 2004-07-23 2013-02-20 エンドサイト,インコーポレイテッド 2価リンカーおよびその結合体
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
WO2006101845A2 (en) 2005-03-16 2006-09-28 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト,インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
EP2374480A3 (de) 2005-08-19 2013-05-01 Endocyte, Inc. Multidrug-Ligandenkonjugate
EP1940473A2 (de) * 2005-09-23 2008-07-09 Purdue Research Foundation Verfahren und vorrichtung für die multiphotonen-in-vivo-durchflusszytometrie
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
EP3000480A1 (de) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
BRPI0722382A2 (pt) 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
CA2669727C (en) 2006-09-27 2014-10-28 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US8685752B2 (en) * 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
JP2010510202A (ja) 2006-11-17 2010-04-02 ファイザー株式会社 置換ビシクロカルボキシアミド化合物
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
EP2604283A1 (de) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Rezeptor- und antigengerichtete Prodrug
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
WO2008125615A1 (en) * 2007-04-11 2008-10-23 Merck Eprova Ag 18 f-labelled folates
CN101646639A (zh) * 2007-04-11 2010-02-10 默克阿泼洛发股份公司 18f-标记的叶酸
CN101646670A (zh) 2007-04-11 2010-02-10 默克阿泼洛发股份公司 18f-标记的叶酸酯
WO2008125618A1 (en) * 2007-04-11 2008-10-23 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
CA2685127C (en) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20090105124A1 (en) * 2007-08-23 2009-04-23 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト,インク. 接合体を投与する方法
CA2708171C (en) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Folate conjugates
CN102006890A (zh) 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 靶向脂质
EP3604533A1 (de) 2008-04-11 2020-02-05 Arbutus Biopharma Corporation Ortsspezifische abgabe von nukleinsäuren durch kombination von gerichteten liganden mit endosomolytischen komponenten
US8546425B2 (en) 2008-09-17 2013-10-01 Purdue Research Foundation Folate receptor binding conjugates of antifolates
US20110230420A1 (en) * 2008-11-17 2011-09-22 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
SG176983A1 (en) 2009-07-08 2012-02-28 Dermira Canada Inc Tofa analogs useful in treating dermatological disorders or conditions
ES2574032T3 (es) * 2009-09-07 2016-06-14 Nipro Patch Co., Ltd. Preparación absorbible por vía transdérmica
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
DK3135301T3 (en) 2010-06-22 2018-06-25 Onxeo OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC SUBSTANCES FOR NUCLEIC ACID CONJUGATES
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
EP2527440A1 (de) 2011-05-27 2012-11-28 Institut Curie Krebsbehandlung durch Kombination von Doppelstrangbruch nachahmenden DNA-Molekülen mit Hyperthermie
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013130776A1 (en) * 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドEndocyte, Inc. 非天然アミノ酸を含む薬物送達結合体および使用方法
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
FR3000551B1 (fr) * 2012-12-27 2015-06-26 Biomerieux Sa Derives de folate, particulierement utiles dans le cadre du dosage de folate(s)
WO2014101134A1 (zh) * 2012-12-28 2014-07-03 Yan Wenguang 叶酸衍生物及其制备方法和应用
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
EP3456700A1 (de) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
SG11201703638XA (en) 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016183131A1 (en) * 2015-05-11 2016-11-17 Purdue Research Foundation Ligand ionophore conjugates
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
US10286080B2 (en) 2015-08-03 2019-05-14 Wayne State University IgA Fc-folate conjugates, pharmaceutical compositions and methods to treat cancer
US10246709B2 (en) 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
WO2017181088A1 (en) 2016-04-14 2017-10-19 University Of Florida Research Foundation, Incorporated Use of mir-223-3p as a cancer therapeutic and method for treating cancer using the same
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
EP3638672A1 (de) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemische verbindungen als h-pgds-inhibitoren
EP3687579A1 (de) 2017-09-25 2020-08-05 University of Bremen Ligandenkonjugate und verfahren zur gezielten rezeptorvermittelten zellaufnahme
EP3461488A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination aus einem dbait-molekül und einem hdac-inhibitor zur behandlung von krebs
WO2019169029A1 (en) * 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
MA70658B1 (fr) 2018-08-13 2026-04-30 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP3942045A1 (de) 2019-03-21 2022-01-26 Onxeo Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
KR102933784B1 (ko) 2019-04-03 2026-03-06 알리고스 테라퓨틱스 인코포레이티드 피롤 화합물
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Psmaコンジュゲートの調製方法
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
AU2022409713A1 (en) 2021-12-16 2024-06-20 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515483A (en) * 1946-08-10 1950-07-18 Merck & Co Inc Diacylated pteroic acid and process for preparing same
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US3392173A (en) 1964-03-09 1968-07-09 Lilly Co Eli Novel acyl derivatives of desacetyl-vincaleukoblastine and processes for their preparation
US3387001A (en) 1964-10-19 1968-06-04 Lilly Co Eli Novel aminoacyl esters of desacetyl vincaleukoblastine
US4203898A (en) 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4166810A (en) 1978-04-20 1979-09-04 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide
US4337339A (en) 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
JPS59175493A (ja) 1983-03-25 1984-10-04 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体
EP0116208B1 (de) 1982-12-07 1988-03-30 Kyowa Hakko Kogyo Co., Ltd. Mitomycin-Analoge
US4866180A (en) 1984-02-24 1989-09-12 Bristol-Myers Company Amino disulfide thiol exchange products
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体,その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
ZA873600B (en) 1986-05-27 1988-12-28 Lilly Co Eli Immunoglobulin conjugates
US4801688A (en) 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
WO1988001622A1 (fr) 1986-08-29 1988-03-10 Kyowa Hakko Kogyo Kabusiki Kaisha Derives de mitomycine
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
JPH06502301A (ja) 1990-08-29 1994-03-17 サントル オスピタリエ レジオナル デ ナント 安定タンパク質コアに結合されたタンパク質ポリリガンド
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
ES2295093T3 (es) 1993-04-23 2008-04-16 Wyeth Conjugados y anticuerpos de rapamicina.
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
US6171859B1 (en) * 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6030941A (en) 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
DE19621133A1 (de) * 1996-05-24 1997-11-27 Boehringer Mannheim Gmbh Bestimmungsverfahren mit oligomerisierten Rezeptoren
EP0926955A4 (de) * 1996-09-12 2003-05-07 Merck & Co Inc Konjugate nützlich in die behandlung von prostatakarzinom
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
AU1095799A (en) * 1997-10-17 1999-05-10 Philip L. Fuchs Folic acid derivatives
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6291684B1 (en) * 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
KR100642955B1 (ko) 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
WO2001028592A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6821731B2 (en) 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002098868A1 (en) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1419154B1 (de) 2001-08-22 2005-10-05 Wyeth Rapanycin29-enole
ES2338305T3 (es) 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
GR1004163B (el) 2001-11-01 2003-02-21 Πολυκυκλικα παραγωγα τροποποιησης των οπτικων ιδιοτητων και των ιδιοτητων αντοχης στο πλασμα των πολυμερων λιθογραφιας
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7000695B2 (en) 2002-05-02 2006-02-21 Halliburton Energy Services, Inc. Expanding wellbore junction
EP2258401B1 (de) 2002-05-06 2014-07-09 Endocyte, Inc. Folatrezeptor gerichtete bildgebende Konjugate
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
EP1575518A4 (de) 2002-10-10 2007-08-22 Wyeth Corp Zusammensetzungen, organismen und methoden mit einer neuen humanen kinase
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
BR0316476A (pt) 2002-11-21 2005-10-11 Wyeth Corp Composição e processo para tratar nefrite do lúpus
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾iRNA剤
WO2004101803A2 (en) 2003-05-12 2004-11-25 Wyeth Holdings Corporation Process for producing anticancer agent ll-d45042
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
PT1658295E (pt) 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト,インコーポレイテッド 2価リンカーおよびその結合体
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ, インコーポレイテッド 化学修飾オリゴヌクレオチド
WO2006101845A2 (en) 2005-03-16 2006-09-28 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
WO2006105141A1 (en) 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
JP2009504783A (ja) 2005-08-19 2009-02-05 エンドサイト,インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
EP2374480A3 (de) 2005-08-19 2013-05-01 Endocyte, Inc. Multidrug-Ligandenkonjugate
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins

Also Published As

Publication number Publication date
EP1389209B1 (de) 2009-04-08
US20040242582A1 (en) 2004-12-02
DE60231868D1 (de) 2009-05-20
US7875612B2 (en) 2011-01-25
EP1389209A4 (de) 2005-04-13
US20110028714A1 (en) 2011-02-03
US20050227985A9 (en) 2005-10-13
US8470822B2 (en) 2013-06-25
EP1389209A1 (de) 2004-02-18
WO2002085908A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
MY154904A (en) Neuropilin antagonists
BR9911575A (pt) Heterocìclicos de alquilsulfóxido 4-benzil piperidina e seu uso como antagonistas receptores de nmda seletivas do subtipo
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
SE0301653D0 (sv) Novel compounds
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0507159A (pt) polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
NO20072004L (no) Substituerte kromanderivater, medikamenter og anvendelse i terapi
MY166050A (en) Antibody formulation
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
UY29700A1 (es) "8-(3-amino-piperidin-1-il)-xantinas, su preparación y su uso como medicamentos
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
SE0301700D0 (sv) Novel compounds
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
NO20082376L (no) Farmasoytiske sammensetninger
DE60326833D1 (de) Vitamin-mitomycin-konjugate
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
ATE514714T1 (de) Hutnfr1-selektive antagonisten
CY1110170T1 (el) Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
WO2008150495A8 (en) vWF APTAMER FORMULATIONS AND METHODS FOR USE
BR0209440A (pt) Sulfonamidas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties